Marine Sourced Compounds as Hypoxia-Inducible Factor Inhibitors
A special issue of Marine Drugs (ISSN 1660-3397).
Deadline for manuscript submissions: closed (2 August 2019)
Special Issue Editor
Interests: natural products chemistry; chemical biology of natural products; NMR spectroscopy
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Hypoxia inducible factor (HIF) is a transcription factor that regulates how cells respond to low-oxygen environments. Downstream target genes of HIF that are activated under hypoxic conditions include vascular endothelium growth factor (VEGF), lactate dehydrogenase A (LDHA), and glucose transporter 1. HIF is upregulated in a wide range of cancers and is fundamentally involved in cancer development, tumor angiogenesis and invasion, and energy metabolism. Inhibition or dysregulation of HIF is an attractive therapeutic strategy for targeting hypoxic solid tumors that are often difficult to treat. Marine compounds that interfere with HIF function or other elements of cellular hypoxia response pathways will be highlighted in this Special Issue. The molecular mechanism of action and preclinical development studies of these compounds, as well as biological probe development and chemical biology studies, are of particular interest.
Dr. Kirk R. Gustafson
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Marine Drugs is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- Hypoxia Inducible Factor
- marine drugs/natural products
- cancer development
- tumor angiogenesis
- transcription factors
- targeted drugs development
- hypoxia response
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
